Sagimet Biosciences

NMQ:SGMT · US7867001049

BiotechnologySmall

360° View

Value43

Price/Sales9

Price/Earnings68

Price/Book41

Dividend Yield1

Growth42

Revenue Growth1

Profit Growth75

Capital Growth6

TSR 52w37

Safety94

Leverage100

Liquidity43

Refinancing75

Combined63

Sentiment37

Analyst Opinions60

Pro Holdings29

Opinion Changes17

Market Pulse61

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2006

Employees24

Websitesagimet.com

ISINUS7867001049

Last UpdateApr 2, 2026

Index & Theme

InflammationDermatologyHepatologyGastroenterologyOncologyBiopharmaBiotechnologyTherapeutics

Description

Sagimet Biosciences Inc. operates as a clinical-stage biopharmaceutical company. The company is developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the ove…

Analysis

Sagimet Biosciences's 360° View rank of 59 places it above its peer average — better than 59% of its true peers.

It's growing slowly (42) and on the expensive side (43). On safety it is very well financed (94), and the market shows muted sentiment (37). Taken together, its Combined rank of 63 reads as above its peer average.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sagimet Biosciences with its peers

Galectin Therapeutics

NAQ:GALT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Madrigal Pharmaceuticals

NSQ:MDGL

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

MediciNova

NMQ:MNOV

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Actuate Therapeutics

NMQ:ACTU

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

RAPT Therapeutics

NMQ:RAPT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Soleno Therapeutics

NAQ:SLNO

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →